{
  "abstract": "Hepatocellular carcinoma (HCC) remains a major global health concern. According to GLOBOCAN 2022, primary liver cancer ranks as the sixth most common cancer and the third leading cause of cancer-related deaths, with approximately 865 269 new cases and 757 948 deaths in 2022.1 Without intensified screening and treatment, global HBV-related deaths are projected to rise by roughly 39% between 2015 and 2030.2",
  "authors": [
    {
      "affiliations": [
        "Division of General Medicine, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan",
        "School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan",
        "Institute of Clinical Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan"
      ],
      "name": "Chien-Wei Su"
    },
    {
      "affiliations": [
        "Institute of Clinical Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan",
        "Translational Research Division, Medical Research Department, Taipei Veterans General Hospital, Taipei, Taiwan"
      ],
      "name": "Yuh-Jin Liang"
    },
    {
      "affiliations": [
        "Institute of Clinical Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan",
        "Translational Research Division, Medical Research Department, Taipei Veterans General Hospital, Taipei, Taiwan",
        "Cancer and Immunology Center, National Yang Ming Chiao Tung University, Taipei, Taiwan"
      ],
      "name": "Jaw-Ching Wu"
    }
  ],
  "title": "Unravelling the heterogeneous HCC risk in indeterminate chronic hepatitis B",
  "uid": "869a54ed-47cd-5cd1-afa1-998c1fb7d804"
}